Sweden’s Active Biotech said its experimental therapy Laquinimod failed to meet the primary and secondary objectives of Phase 2 clinical trial evaluating the drug’s potential to treat primary progressive multiple sclerosis.
Laquinimod, ... Read more
A national survey in the U.S. revealed that 98% of women newly diagnosed with multiple sclerosis struggle to discuss important personal concerns with their healthcare team.
The ... Read more
Pin It on Pinterest